Bristol Myers Squibb (CELG-RI) Amortization - Intangibles (2019 - 2026)

Bristol Myers Squibb (CELG-RI) reported Amortization - Intangibles of $437.0 million for Q1 2026, down 47.35% year-over-year from $830.0 million in Q1 2025, and down 47.09% quarter-over-quarter from $826.0 million in Q4 2025.

Bristol Myers Squibb (CELG-RI) Amortization - Intangibles (2019 - 2026) Analysis & Trends

Bristol Myers Squibb (CELG-RI) has 8 years of Amortization - Intangibles data on file, last reported at $437.0 million in Q1 2026.

  • Amortization - Intangibles for Q1 2026 came in at $437.0 million, down 47.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.9 billion (down 60.19% YoY), and the FY2025 annual result was $3.3 billion, down 62.61% from the prior year.
  • Amortization - Intangibles eased to $437.0 million in Q1 2026 per CELG-RI's latest filing, from $826.0 million in the prior quarter.
  • Over five years, Amortization - Intangibles peaked at $2.4 billion in Q3 2022 and troughed at $437.0 million in Q1 2026.
  • A 5-year average of $1.8 billion and a median of $2.3 billion in 2023 frame the typical range for Amortization - Intangibles.
  • The sharpest annual moves came in 2024 and 2025: Amortization - Intangibles rose 7.04% in 2024, then slumped 65.65% in 2025.
  • A 5-year view of Amortization - Intangibles shows it stood at $2.3 billion in 2022, then dropped by 2.77% to $2.3 billion in 2023, then slipped by 25.68% to $1.7 billion in 2024, then plunged by 51.21% to $826.0 million in 2025, then plunged by 47.09% to $437.0 million in 2026.
  • Business Quant data shows CELG-RI's Amortization - Intangibles at $437.0 million in Q1 2026, $826.0 million in Q4 2025, and $831.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Bristol Myers Squibb - - 8.07 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 437.00 Mn
Dec 31, 2025 826.00 Mn
Sep 30, 2025 831.00 Mn
Jun 30, 2025 830.00 Mn
Mar 31, 2025 830.00 Mn
Dec 31, 2024 1.69 Bn
Sep 30, 2024 2.41 Bn
Jun 30, 2024 2.42 Bn
Mar 31, 2024 2.36 Bn
Dec 31, 2023 2.28 Bn
Sep 30, 2023 2.26 Bn
Jun 30, 2023 2.26 Bn
Mar 31, 2023 2.26 Bn
Dec 31, 2022 2.34 Bn
Sep 30, 2022 2.42 Bn
Jun 30, 2022 2.42 Bn
Mar 31, 2022 2.42 Bn
Dec 31, 2021 2.42 Bn
Sep 30, 2021 2.55 Bn
Jun 30, 2021 2.55 Bn